Möchten Sie immer auf dem neuesten Stand bleiben?

NRx CEO presented plans for HOPE Therapeutics rollout in September 2025 and establishment of flagship location in Palm Beach, FL during symposium presentation with leadership from Rockefeller Capital...

US Food and Drug Administration (FDA) has granted Fast Track designation for NRX-100 in the treatment of suicidal ideation in patients with depression, including bipolar depression.NRx Pharmaceuticals...

NRx Drug Development Grant of expanded Fast Track Designation for NRX-100 from the FDA for all indications and types of depression and related disorders based on its potential to satisfy an unmet...

WILMINGTON, Del., Aug. 11, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that...

AUSTIN, Texas, June 24, 2025 (GLOBE NEWSWIRE) -- via IBN – NRx Pharmaceuticals Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has selected IBN, a multifaceted financial news and...

TORONTO and HAIFA, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a preclinical-stage biotechnology company...

TORONTO and HAIFA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company...

Company reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to prior year periods Company reports 23% prescription...

SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

NurExone Biologic Inc. announces formation of a U.S.-based subsidiary, Exo-Top Inc. for fully characterized GMP Exosome production.